{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Cardiac troponin I (cTnI)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Fatigue (asthenia, lethargy, malaise)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemorrhage, GI - Duodenum"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemorrhage, GI - Lower GI NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypotension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lung Infection w/normal ANC or Gr 1-2 neutrophils"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Skin Infection w/normal ANC or Gr 1-2 neutrophils"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infection-Other (Specify)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Mucositis/stomatitis (clinical exam) - Oral cavity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neuropathy: sensory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Phosphate, serum-low (hypophosphatemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Potassium, serum-low (hypokalemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Rash/desquamation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Rash: hand-foot skin reaction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sodium, serum-low (hyponatremia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Syncope (fainting)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombosis/embolism (vascular access-related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombosis/thrombus/embolism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ulcer, GI - Duodenum"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ventricular arrhythmia - Ventricular tachycardia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Only adverse events that are possibly, probably or definitely related to study drug are reported.","groups":[{"description":"Adjuvant Chemotherapy:\n\nCapecitabine, 1500 mg/m\\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\\^2, IV, Days 1 \\& 8 of each cycle.\n\nChemoradiotherapy:\n\nCapecitabine, 1330 mg/m\\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.","id":"OG000","title":"Adjuvant Chemotherapy + Chemoradiotherapy"}],"paramType":"NUMBER","populationDescription":"Eligible patients who received any treatment and were assessed for adverse events are included in this summary.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","type":"SECONDARY","unitOfMeasure":"Participants"}